0001193125-23-146528.txt : 20230517 0001193125-23-146528.hdr.sgml : 20230517 20230517070900 ACCESSION NUMBER: 0001193125-23-146528 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230516 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230517 DATE AS OF CHANGE: 20230517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35006 FILM NUMBER: 23929615 BUSINESS ADDRESS: STREET 1: 11500 S. EASTERN AVE., SUITE 240 CITY: HENDERSON STATE: NV ZIP: 89052 BUSINESS PHONE: 702-835-6300 MAIL ADDRESS: STREET 1: 11500 S. EASTERN AVE., SUITE 240 CITY: HENDERSON STATE: NV ZIP: 89052 FORMER COMPANY: FORMER CONFORMED NAME: NEOTHERAPEUTICS INC DATE OF NAME CHANGE: 19960819 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 8-K 1 d449587d8k.htm 8-K 8-K
SPECTRUM PHARMACEUTICALS INC NASDAQ MA false 0000831547 0000831547 2023-05-16 2023-05-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2023

 

 

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35006   93-0979187

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Pilot House-Lewis Wharf, 2 Atlantic Avenue   6th Floor Boston, MA   02110
(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (617) 586-3900

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   SPPI   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On May 16, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market because the Company’s common stock had a closing bid price of at least $1.00 per share for ten consecutive business days.

On May 17, 2023, the Company issued a press release announcing that the Company received the Notification Letter and regained compliance with Nasdaq’s minimum bid price requirement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description

99.1    Press Release dated May 17, 2023
104    Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        SPECTRUM PHARMACEUTICALS, INC.
Date: May 17, 2023     By:  

/s/ Nora E. Brennan

    Name:   Nora E. Brennan
        Title:   Executive Vice President and Chief Financial Officer
 EX-99.1 2 d449587dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Boston, MA, May 17, 2023 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

About Spectrum Pharmaceuticals, Inc.

Spectrum is a commercial stage biopharmaceutical company, with a strategy of acquiring, developing, and commercializing novel and targeted oncology therapies. We have an in-house clinical development organization with regulatory and data management capabilities, in addition to commercial infrastructure and a field based sales force for our marketed product, ROLVEDON™ (eflapegrastim-xnst) Injection. For additional information on Spectrum please visit www.sppirx.com.

Notice Regarding Forward-looking statements

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, the possibility that our commercialization efforts may not be successful, our dependence on third parties for manufacturing, distribution and quality control and other risks that are described in further detail in the company’s reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

LOGO

 

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and ROLVEDON™ are the Spectrum Pharmaceuticals’ logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2023 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Contacts:

Nora Brennan

Chief Financial Officer

949.788.6700

InvestorRelations@sppirx.com

Lisa Wilson

In-Site Communications, Inc.

212.452.2793

lwilson@insitecony.com

EX-101.SCH 3 sppi-20230516.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 sppi-20230516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 sppi-20230516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g449587img1.jpg GRAPHIC begin 644 g449587img1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 16, 2023
Cover [Abstract]  
Entity Registrant Name SPECTRUM PHARMACEUTICALS INC
Security Exchange Name NASDAQ
Entity Address, State or Province MA
Amendment Flag false
Entity Central Index Key 0000831547
Document Type 8-K
Document Period End Date May 16, 2023
Entity Incorporation State Country Code DE
Entity File Number 001-35006
Entity Tax Identification Number 93-0979187
Entity Address, Address Line One Pilot House-Lewis Wharf, 2 Atlantic Avenue
Entity Address, Address Line Two 6th Floor
Entity Address, City or Town Boston
Entity Address, Postal Zip Code 02110
City Area Code (617)
Local Phone Number 586-3900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SPPI
Entity Emerging Growth Company false
XML 8 d449587d8k_htm.xml IDEA: XBRL DOCUMENT 0000831547 2023-05-16 2023-05-16 SPECTRUM PHARMACEUTICALS INC NASDAQ MA false 0000831547 8-K 2023-05-16 DE 001-35006 93-0979187 Pilot House-Lewis Wharf, 2 Atlantic Avenue 6th Floor Boston 02110 (617) 586-3900 false false false false Common Stock, $0.001 par value SPPI false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityRegistrantName, dei:SecurityExchangeName - d449587d8k.htm 7 d449587d8k.htm d449587dex991.htm sppi-20230516.xsd sppi-20230516_lab.xml sppi-20230516_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d449587d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d449587d8k.htm" ] }, "labelLink": { "local": [ "sppi-20230516_lab.xml" ] }, "presentationLink": { "local": [ "sppi-20230516_pre.xml" ] }, "schema": { "local": [ "sppi-20230516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sppi", "nsuri": "http://www.sppirx.com/20230516", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d449587d8k.htm", "contextRef": "duration_2023-05-16_to_2023-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d449587d8k.htm", "contextRef": "duration_2023-05-16_to_2023-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.sppirx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-146528-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-146528-xbrl.zip M4$L#!!0 ( !TYL5:>K0'A?P\ ,EH . 9#0T.34X-V0X:RYH=&WM M'6MSVKCV^\[L?]#0[0Z9"0\#>4 >=RBA+;,)R0*]NW._=(0M@FZ-Y95$@/OK M[SFRS=,$2""D;3+3QK9DZ>B\'Y)S_J]ASR4/3"HNO(N$E!P.,:V7^OKENVEW6HRGN*4T]>SQ#7\NE\!0ST!IUY$H4 M M,)S.J(._-="2[A68]I2G"$%/NGSQ\N$A7A:>;I5 MX,T'LX.XB MH=E09\R()(/O9<)!"2'G;>&,+L\=_D"4'KGL(N%PY;MTA/S/$I?DG ]+V)W) M\)H[#O.":^A2#YB?<.C5==H#@#SX'R9@O!3? M;@ >Z@;K0*^^-/3XBIR=RAZEK..O6DS=)2Z;=]5*J_'EAMQ]+C=NRI7JEU:M M4KYNDEJ]K=LWEXX]LWA+=>;EZ5_]P0L@!39<>1 M3*FFIIK=RCLI'KAAN'F,+NNW(:0WY5503B8N]YCGP#_]T:7W&\_4H:YB3T)) M!::4U*UY#AO^P4:+N%CHL"%H6?@YS5M'A9-%^#)SDB!9ATDP54S!/>KMDC(: M%N8B1N67T%Q<)!3O^2XJ"O.L*Q$4U.*I2'^GA\J)FJFTI4"17-M"[,#V7)YG M9M<3KGYFQ>9>B;X,;HW"+(7H-M1; ]W1:\P0;WS+'7S0X4P2 P*+5>>5VA^S M!)M_&:&.'=\'B@IG? N:7.HKD)[+"6S1FY.V":S.DKY1RWC:\3R9&>R,L3G! M7F9:XV9 ,\.O*?V,;Z6HR^^]D@UK83(QVS[@CNZ63M-'W#N;ZNNRCC[K47G/ MO11>EPCM:Q$]D?R^&S["X?QH,#22J2XSK>".^>,AM/!+4[=MH;7HF2=M(0'T MZ(GE#XD2+G?(NZSY25S^_LXZSIZ=9_QE$^573Y1[\D13PQ9@$+*X -(!TJ04 M_Q\K6:?C^P[M<7=4:O$>4Z3.!J0A>M0[,VV# .ZV<)VS&/)\J==:U2O2;)5; MU>9R<+(O!$ZS6OG2J+5JU28IUZ](]>_*YW+]4Y54;F]N:LUF[;;^+!ASVX#Q MKW+S(<7%.3KL.9LPRQ2J)B.?/X29R9SD*W6>8\ M"Z0T9[U?7/V:4CI93*0DX@AFO117?;QMW)!SY5-OK(BZ7+,4/+$9&,^!I#X8 MDV5>Q)6P^^A$3'FNZUMJXQ7/FNCS#()R^<8Q.^&8K<@X:*%&M=XBC>K=;:.U M?YUSUY>J#[$(T8* OX\\%V#,RI/;!K&.DL[!_J$4'=+J,A(&)!S>CV(24K8U M@6:KF"\LA_/%R(ON#X+38+Z0FB2C>T;!_6%*$_8 /8DTS82TJ$Q(<^2_NPVEIFL#BE(.8H& MRI(<+X-0193/; QV',(]PK4BH!= M.2\UGICW"6,^QS$8(J.MEU&;.:ZZ/28 MG'4V8>Y]ZCC1?3A7N%9;N"[U%2M%%X_SR!1#H=<68,/*9M^'N"ME0S!+V2B8 M0\!D\,N9C1'SA?<8WFMGKO6!2,L5-9(:=2H:1R-Q:@"< PFF5 M,R^]C_BZ@0JJ>;:08/N,V3()NXKH>UJ.*L)YEG%#W8>Y"LU\*1YP6K1N5\RE M S!T2QWE==D@XOF%_CO!X9,#B@#)'[G+H*T-NFGS])^5RA]EL\=+,?8C(ZY% MA[4P>68;3#T1BT6X*IX4K=.%)&H,&G;&&4CI\3: 7#@A_!I7780V-;]B,5^R501O1Y7ZC50!34?"83V)R9( MK=$DU9[OBA&3>R?)K$(E=9&>4,:H/O@/799;&E:0 MPU_7$,19&QO].^X*33Z+OF*I:S;@BOP%D6CGD.1(6;L0K<*\Y0?F]5^1-[HK M[.4VQMZQ[I*/KA!R_1K\S.05N+R5+3'P-I[Z@U :;=?LO(<;)E>6;$(PNPJB M1,H/0>8[0!=U_\/]IX1LE]F<964?$X#7[ ZOP%\RQ! FJ7P)Y.<^=0D;,KNO M^0/FKL ,,G6P/4:(!?)UQF9)X!B"+'.P0.T8#V##W/U6THR3].CO[TYSULF9 M CRXS.\*CQ'/.)6'Z/2[??0A" 6&!.X';ERNHE KE:'?DT0E>6R='"RJPR?' MN-<"*':'JWEB6'MT>IS*%[/+Q?MD+ .%KCL^R[P)C#48AVF)(VLP5 R0;-B)Q5XNC*=,'#D"'NZ@XP#/DN$?5 ;)K 93O M]5U-/0:>HSLB"J10=49FAO %T09\!>&3"*:>*H'T81Q@*6\4M74@@!$#? \S MH1SC0GSAC^8H/#^+-:&+=.=?TFN M@628ZNA[82RKGIVO;@OAMBF02P-S(9:+)X7"V:)Z7R?=(Z(96/#9++9]/0<9.\P!O; MKL6V3=#"-B#7:"#!@ZP,8BPZ[4YU:!IJQ ?R!A6,F9@+64 M/86VB.-7:?PU!,A)Y9+M@^V*4##FFQ"]D!#5E.HS^29*>Q:E/$L5DO9V12D< M4E!G$.DQ I^4LWJJ+@1\$/+'=YK/,=%)/>]C>]8(IWC<3%DM7& MR,Y>BZPM/!P;[#.VN\1VJ5(O5?Y^*A+W7"1O28K"N_?R>'/4@Z:D>K'M"M\I MO>KAYE_#X"RT;GNGGO (Z * :&*H9NWE*ZR8K\@8A&>^K5S;*)6-BP3H)0): MFEK8WP[);UE@,(OX5)('ZL:5OO=4K%JV_E O!&+YA,/Y=[77LL2UZ]>QQ_PO M\;Q-G2J'_D,JU.>:NN2&RF],3\K9+^D4UCP''65&VB-BF_P\C/@-I(^9O8%S M27&N""P=G&V<])[<2S'07?2W?4R44T4<&8@R%-FCR(7"($O!YR_./[#J(1/ID!*L'[+Q9O[A)=P-:=1Q@5J\VQ7,\7 MJD!=X&GF0E@$/.T)$R3U%3.] $=AK0D_^<)-&2DXEX\X,7.Y(YQ\P&%JE \/ MX(,6R1ZX@O= 4JAG8[:4VC;NUL?.^/$7ATI'!54FY]$(+9^DXPAMFK_3TUPP MIL#VJIX_VHG^H/09%D!__05L1"QGLMX"8^*C*>^CS8#TX'VX SI2B>",%WYV M9^RI0. J9.E=T?R<10ORAS/IJ4P(Q./%Y>U^IN'77Q82WU= MOFM62]'%ZT[ 659L!HZ82V"DQ=32XIZ:FF:]@#M.TUDK9EO1]&#[RI<]YD<' MJ[PU)KR*)V-5FFR2<#K>A@Z^],VG[V:(@9VCH[ "UL,_X ZG40EEQ! MO7.;;1. NIC:H'W-8!:Y!)B.%#VCQ:_!\* 9^+,/0W3&*I-@"'2 9#Z:#=I,;[,[:/XU?, N.' M'7OQM4L"\1TQ*_,R9-YA:7%BXKPH!Q^HZ.CK)@XY*Y@]"FHI'LPPQN MV L0N]2A)FUFT\A:5R+W*-R!9@?AE#)(1. IL5VA<,P)A 5+--EN'OH-PSI MT< 3!8S+##Q!I=Y3T4;$=A\&P(V*#JC_]",G?(-#\5L5L)-(P*:IPK&<@&OS MS?Y)R7 M#)P1#_P-.Y:08[G AS$<#"\_0NF $&,L/TKT-"G#^_YX@\TLC!AJ M:$W!.W,(J#$&S@]%+[[+VUR38C%M&4C,II_HO%#8%8*/-BXD_*;4 B&FD'SZ MW"K5FY',GA6_9R/Y<>R%FRWFR)C*<%;(:ONPG$GG8&[Z>.[-[;KNLAWN7J/P M@OYN6'P)+YP Y='=.F62)16:H+&8?ZDR2EA!+ MU$7ZB1OCU]T>OU[U9BW97@-+)/JFJ.'D%'+NL_+/>)I=V9+[T?G7"9-,N#)& M^!8SQM'V7FR)P=I4,]@]%#_@DMP+GP-;5,"Q=$/[NBMV"1+%E 0?K'0*A>+1 MZ8G#AL6BE>[JGJGK@R/0"!T!Q]CU!4<'U")=BKJ?A4Q6MK!3*E4$/"5WL$*( MSD";4=OXN5=44V+.!"=9K\T.%SIRP>>0"7X/F3CAUY8.IJ5J;$+Q MMDQ_&BU(MXY# K5FXOXP+D_K]-T1 M,1&?$R3G@P,?.$T;_'58+32(X&-&;=:E;@?#!!S([.\).V T??@'3,<$*W3+RF8C/C+0T?9!*[STR>QGGDU\I?TGIC._ MTEU=ZWMIS_7*4$@?L_>F?='@[ZKO_AR)X&.*I46/:G>\LY,3N;$.T8=1:5?+ MV,+NM!4EJ0WM:$9E2%U(2JII\D$RSZ/>BV^2V=%!Z;WS$>[5>%E.6J#DFPEZ MUG%]L\MJ9R3$'$N4]?\WYK4Q9C5_(,#D#BM=SCIDDEJ\-5\HD.O&0.>9X ^I MF#^S#DY,2YH=&V]66M3&SD6_4X5_T'EV4E!E3&&A/ RKC'&@*N,86TGV>PWN5MM M:^B6.I(:X_SZ.5?=-LT[.P.;(H7=>IW[.O>T:)R/+GK-QGFG==)<76F,NJ-> MI]GYS\;^?FVKL9E_Q?/-8@)K'%^>?&?'9^W+WN7@J/+MO#OJ5)IL=063VD(Y M89J-D^Y7-AQ][W6.*C,9NNG!7FU'J@KCL9RHHTHL(E?Q>UTMIB7<3*3:<#H] MJ*?ND!7?Q]HYG>2/(JW()S*>'XQD(BSKBQD;Z(3CI%:O>]8_ MJA@YF>*HQG&S[D$HF6'8L0W9E)$8'XDX=,F]45-Q4L'R0/#:R RU\*Q7J^]<-YZCK:,:\HML%&^ 5OP(.%H8E)D MVQC9EOIL,Z5LLS@@T@9SI5KDY\*"018+MK.S4U_CZVO;ZS7V[FDY*AF6&G$C M=6;CDN^?]GCN6CSI(^S)6)@BCCZ,V]7<9])9]XF9:(,G-\+X,C&<[_R"4?;&AM*"AS&5;5D%P4X1 J;Q(?8&X.(^1E;+QR<^V>9U=MDZ5V. M[Y1S/(BU)1QEJU=7RH7Y^?"!]PC56* (@";W3PJO6%0F%ALV,8(#1:Z! M.W7J/Y._[W:6/RDF+W$K FQX*BF9OPF$&#G)%6N<7O9'2UTSE4YLV!2X#A [ M3*\TX8>V3":LKR)\LYDZ;N<<3A],M1"B6'2149#F]D@[.[X<,S.%CL>$% MW0&2 7H(W?,C]!!6-=F:B&*>B@GAD!\B$&3YNQ%I?TW>DJ_/QLD#4;;XB?]ZD=@!K1"P" K?$0KFS$H@!L*GO M!-'S(,W2DBCS^8(#WA9GH<@;I[96 M^LK,Y=?C7B-NBPY !RM$+C39!$>H4*+*A?7!@AJ@ZH.S+(]\VQ$X*J!66'WR M'%^XC[;F*7K/0J8!,*T\/6GY<4V,QLH\,Q$JD"4 A3:A70#%ER38 \4K(%S@ M6(7U0(;#$8E'L$CK/H?K@#__"J/#IT+=<;HGZ)S.[S'84X$E:?8" MIG)'RJEO@;+D%)L% :H[RK 3+0I%*E0H?#DJ$A$&U,V-KRGB=(0JBRA[BRZ( M8!@YSOSVA/T'R7F7,X31<3D[[BJ!JBH4-L!*5!;Q2&;\' @XV$35G0NNN]<: MRG8C4@\_\HITH=P+SH"X,[Z%^2,[MP$"./$Z*I%P#G6%T=V6+-3"YI41<]_H MLI0T2NJROB M-A"I>RB&8SZK%;3O*7_SI/L5GXO[$+S&^Y]&"I3S6-QO4B)YU GH48H2W1A# M?UYOC 4 B@,>SZ"'Z5:@<3Y@P^Y_D;0?*XLM_7W,P6_[_E^%?>N>C,Z/*EOU M^N_+VY!VIS_J#/[F9Q[S?O1*UW.%5IST:?+E@ M5^>MP46KW?DRZK9;O2$T<[]=\TF G_]1/(&:"^U4; ]#'XARD8%"THSR-Q0 MD%PCH?N*<*<*H#=%O'B!=(B0T.DZ)YW3;K_;/V/M5K_=&>#7H/,W\9;$W@(P MG4F?WT _4N(TB83\Z^-S:L.S#H-@UX5J63C(,CU3>6&^XJ<6&"%GO]+BQ<%H M45 _;E[<:DAJH#;-NY,_P5@?[O>_3X W/@0ZG1_ZE]V715AN63ZG%<<0.).I MH[L\*PS=/918ZETU MW?_XWMF&!(AGWO=_2(6W;P%E-*?0,XK]\S('Q7YY\AT/_9^5_@)02P,$% M @ '3FQ5D>#!E0\ P 1@L !$ !S<'!I+3(P,C,P-3$V+GAS9+U6WV_; M-A!^+]#_X::G#9A$RX;31DA2M$L#!$BSPDV'O16T=':(4J1&4HG]W_=(2;;L MQ)Z3%/6+:=Y]=]_]I$_>+4H)=VBLT.HT2I-!!*AR70@U/XUJ&W.;"Q&].WO] MZN2W.(;SB\MKB.'6NW(@DUR73*(XT[_KYNO\$]C/8,) M2N06H>36H8$/M9!%-AP,AVDZ>)L<]6$&N;<'!7>8P9BE;Q@ICF"4#4;9> 2? M/\''8$7!C2BQ#]75THCYK8/?\S\@@,ZU4B@E+N%"**YRP25\Z1C_"92O7P%0OI3-%)FLR]/()Z+-PV)J9*+-G!7. M,+>LD)%23%IH1![UH/^/>X"A0GB)70%GW$X#J)/X] Q["%M58L.-OS"+4!^? ME,$X/>JI%[C6#H0LYLE0! M:#U15MHX:#KP2N=A,/8DT_^*NQK$_BI.A_$H3?'AT4_X-E\!.8:'7]4C*]C?;\ MFB@N\F9A-ZWA[B;1>@T^NE';!49\)I_%7,]U>T:5O MXJSKY G.("ROC)O<:(G[5QRKC*[0.$$+?CT,C8%;@[/3R&^;N-LSWR2?)K1G M.I4'#C;'RXL905!>K>EU6">AZ8XPNM=+EL*)[KO/;O3_?] M7A4?%1%;7E)?F3*0BD#0.S(A]6\'J:\H=B0+I+]M(C1O.O ?^E?76>@?N2J@ M,0<]>R=LV\BV_=IB\;7#7;AG[^ %!+ P04 " =.;%6+$-BJ8@& "Y1@ %0 '-P M<&DM,C R,S U,39?;&%B+GAM;,V<;V_;-A#&WQ?H=[AY;S:@LF,;W5:C:9$Y MR1 L;8+&W88-0R%+C$U,(@U*CNUO/U)_&BFF9,H\57G15I'NGKM'^9&5*ST9#_*4WF/&=B]E,TX2AF_>O!DD1XO1$=7%2O'AX*\/UW?> MDH2N(\^^_&UY69F(3J)D_S7WDE-HT"!41JB?G#S,4;N&D>B^+CWG&Y7J!.$1?YSL3$:4^3 M-"@WI.+.A%?2]M%3N)8IY^+WBH[2(KQS4'OP3S0-NF M(DENJ=%-F//Y[I#75*AH3)"(KX7$J\FO-O'S+E&&?W+M?]\.'FL_EU;E%!*1 MZZ;]VB%YP6(:[SZ1!56%6/S1#8DIF?K]OHL(-VW>#N0[XJV%K'>Q]9;2/&D"LCZW(Y!KC?#J&!N0J_600,X+0%X! M!^3V^BZ"W+1YC!GYS/=EV]%=+"\Z;\2MX ^4>0UGYBJ-3F?H \;XX5C[&;M. M%W?FSBJ]@J06< %Y-:1)O$TKFLG\&#]VP^$LE-?A\D]\&;@+4_Z?)'4$O+YU MKCEH@[1&"(GAK\J@I*V!;:'1(J&FW6+,SE-91KC!E?R$N/V=[)I-RWO)G<[' M559X39#]#*P5Q)UZLQ*0U !9!&G&;:5US53;H'\[I,^YMU;C9B:[-R6YG-,1 MP-K&^?XQ&USW=9 HS85!*5NCB=]FD4C#7G$PO"6"?R"J,ICT^2.P93 M;X77!&&@JA'$9C8M ;(&J")H^+;0NI9CX_XQ+A:NF,?%BHMD"3RY;I[RM9S; M=U/N-_Q$=T"JTPL),YO<.,7^(L- 'O>2HU0P^XB4E015$^D*Y!OXTER/'&\. M8Q!=TH!\7(=S(IJ-F&)>I\-#8X#KC]N#_U0+EW*E#JD\$M#8_6KH-6H: ]29 MN[WRY?\Q])ZF-SV/H;92I%.$#UGC!L'V<-<*XY(N2T&Y%B[WK5K1#((C_""N M96?_7%-&AD$-&?RLT;,>,;=A3X MQ?3G@+W&C@[ZQS TY)]*M@2\*J/NZZE"N+!C&ZA#WEX+T6B(:]1;8GZM!+(4I@+->W9J&/?V(OEPZS*H"!N$^#+.5T] MRJIKG.\?LWJ0=4\'"=QD8E/*.)SB]UEZB-6P63L0U=/EP>V2LX8+A/MY'0%9 M:8#KC]N J=="@C,1AT0=:Z&DG7Z+D#9IV@[4/P6-8\*F/ S7+%N B4QIK4CN M"-EZ*[PFR ;>&D$D@K,*4"YA37&+C1=1;MJ]Y1/7/* >C2E;?'!E%]0-3%G6 M97;UM'6U"5X58?6D=84:$K^/\I#KVS]DW5++I4>LF_1MA^VM(&I\$(E%\L2, M>LU+W-S?FU\XU"ETA+&!*7XHT@;K0ZI(>,LR4*P#:2%(*EF#WK:)(O!'.D%% M_RJ*UD38#P"-SO,8!M4&]8-A+QYQ2%1HMS4PTG*MCH^6'-6.DD:V<%XH&X[F M,QH'C5\F>\SK^$6R/0-_P%02P,$% @ '3FQ5D\H&27+ M! .RP !4 !S<'!I+3(P,C,P-3$V7W!R92YX;6S5FF%OXC88Q]^?=-_! MR]YLTD((7'M75'IBM)W0:(N VZ:].9GD :PY=F2; M]^=L"[!$)'>K2/I81(1Z2"K,84\Z@ MZVU!>A]OWKZY_L[WT>W]X!'Y:*E4*CM!L%ZO&_&<,,GI2NF0LA'Q)$"^;^OW MIY_0;[OF.F@,%+ $E&"I0*"?5X3&G5:SU0K#YH?&95XF )MX*,8*.N@B"-\' MNF(;M3O-=N>BC48/Z"Z+PM"4))"7\G0KR&*IT _1CR@3W7+&@%+8HGO",(L( MIFAB'?^$!BQJH!ZE:&QD4MN4()XA;NRC4L+^ZIA_,V,>O7V#])_.(Y-9:=92E_HQNH9,US"_?5O--D1^V M_';8V,C8NS%-[K(J.(4QS)'Y_#0>%-J4:4K$)AM0&?OF17@9*+SAC"?;P"B" M6QZM$F#*?O98?,<44=L!FW.19/WP4);2SE+ O.N9H+Z-9MQ\/]:!/E<)I+:I M/BLD25(*'@IRO4F%'CE,9;6'NJ @@(T"%D-LPY@._"?]O=D1W0];'A7Z;T_< M#)>$J+'@ST$,Q+38,E],3"J!(U5, #7CA M;2/$,:-J4>WF$/1$5(F,1V:CZZQ&_XAFPKQ&D6.AX M?K34+&$37TSG1$X"'4D&XT-5TB8=64EOBJ3&/J3D& M?2*FKJ"ZGHT[+YX!R;$6BO^A8YOM63>%5(!^+ZTSHP;+%=.8/-KF4B+E(N MLMQFE]\^7^GI8MOG<<5[CW\)55^D9]G? VXW'0-\3R@\KI(9B&HT\[JZH\M[ MM9Q"QSA-\680ZS20.=EM";T&VLD@=2=XTKC%Z?: M(GW?E1&7"M,_25K]CK0\@B,(#UQ;BNZLVN;-1,A)@AARP"+)]6//F@'B: MS\^?%E^*4%]Z+[FV%-W91CGHS4#*%8BO9UD2QQFB)=XM5W?V4^Q#_K UFQ)% M*[_,\$577V['7BTG=S9-I@*;%QLGVV3&S[[<'8CJ2^C J,7CVH;(70)BH?OQ MB^!KM=1S18I9Q#DY,2YH=&U02P$"% ,4 " = M.;%61X,&5#P# !&"P $0 @ &5& &UL4$L! A0#% @ '3FQ5D\H M&27+! .RP !4 ( !NR( '-P<&DM,C R,S U,39?<')E :+GAM;%!+!08 !0 % $ ! "Y)P ! end